Suppr超能文献

一项针对整形外科学随机对照试验中功率和样本量报告的系统评价。

A systematic review of power and sample size reporting in randomized controlled trials within plastic surgery.

机构信息

Hamilton, Ontario, Canada From the Division of Plastic and Reconstructive Surgery, Department of Surgery; the Surgical Outcomes Research Centre (SOURCE); and the Department of Clinical Epidemiology and Biostatistics, McMaster University.

出版信息

Plast Reconstr Surg. 2012 Jul;130(1):78e-86e. doi: 10.1097/PRS.0b013e318254b1d1.

Abstract

BACKGROUND

The randomized controlled trial is a reliable study design for assessing the effectiveness of a surgical intervention, provided it is adequately powered. This systematic review examines the appropriateness of reporting of power and sample size in randomized controlled trials within the plastic surgery literature.

METHODS

Original randomized controlled trials published from January of 1990 to December of 2010 in nine high-impact plastic surgery journals were appraised. The data extracted from each study included calculation of power and sample size, number of patients, and effect size. A Jadad score was calculated, providing a quality assessment of the randomized controlled trial.

RESULTS

: Of the 736 original articles, 463 met the inclusion criteria; 88 (19.0 percent) of these 463 reported performing a priori power analysis or sample size calculation. Of these 88 studies, 68 (77.3 percent) had an adequate sample size. In most studies, a standard of 0.05 for the type I error and 0.20 for type II error was used. There has been some improvement in the reporting of power and sample size in the decades from 1990 to 2010.

CONCLUSIONS

Nineteen percent of 463 randomized controlled trials in the plastic surgery literature reported performing an a priori power analysis or sample size calculation. The implication is that when we read the results of a published randomized controlled trial in plastic surgery, in 81 percent of cases we cannot trust the findings. Although the reporting of power and sample size has improved in the last decade, it is still inadequate. Lack of such reporting casts doubt on the validity (truthfulness) of the study's findings.

CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

摘要

背景

随机对照试验是评估手术干预效果的可靠研究设计,只要其充分有力。本系统评价检查了整形外科学文献中随机对照试验中关于功效和样本量的报告是否恰当。

方法

评价了 1990 年 1 月至 2010 年 12 月期间在 9 种高影响力整形外科学期刊上发表的原始随机对照试验。从每项研究中提取的数据包括功效和样本量计算、患者人数和效应量。计算了 Jadad 评分,对随机对照试验进行了质量评估。

结果

在 736 篇原始文章中,有 463 篇符合纳入标准;其中 88 篇(19.0%)报告了进行事先功效分析或样本量计算。在这 88 项研究中,有 68 项(77.3%)有足够的样本量。在大多数研究中,采用 0.05 的Ⅰ类错误和 0.20 的Ⅱ类错误标准。在 1990 年至 2010 年的几十年间,功效和样本量的报告有所改进。

结论

在整形外科学文献中的 463 篇随机对照试验中,有 19%报告了进行事先功效分析或样本量计算。这意味着当我们阅读发表的整形外科学随机对照试验结果时,在 81%的情况下,我们不能相信这些发现。尽管在过去十年中报告功效和样本量的情况有所改善,但仍不够充分。缺乏这种报告会对研究结果的有效性(真实性)产生怀疑。

临床问题/证据水平:治疗性,IV 级。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验